Acute megakaryoblastic leukemia (AMKL) is a rare type of leukemia characterized by indefinite proliferation of megakaryocytes 1 . The prognosis of AMKL is dismay and no target therapy is available that urges for development of novel therapy 2 . Recent research proposed that forcing AMKL cells to undergo polyploidization and differentiation was a good therapeutic strategy for AMKL 3 . Thus, regulators controlling megakaryopoiesis could be potential targets for AMKL therapy. ANP32A gene was implied to be a potential regulator of hematopoiesis and megakaryopoiesis 4 . However, its role in blood remains unclear. In this study, we observed a potential correlation between ANP32A downregulation and megakaryocyte differentiation. Hematopoietic stem cells (HSCs) (CD133 + CD34 dim ) and megakaryocyte-erythrocyte progenitor expressed a higher level of ANP32A than colonyforming unit-megakaryocyte (CFU-Mk) and mature megakaryocytes (Fig. 1a ) 5 , and significant upregulation of ANP32A was verified in primary AMKL cells (Fig. 1b) . However, ANP32A was downregulated in leukemic cells undergoing megakaryocytic differentiation (Supplementary Fig. 1A, B) . Interestingly, complete blood count of Anp32A −/− mice were apparently normal (data not shown). Both Anp32A −/− and ANP32-overexpressing megakaryocyte cultures showed comparable CD41 and CD42 expression compared with wild-type (WT) cells. ANP32A-deficient megakaryocytes only exhibited mild increased of polyploidy in CD42 + megakaryocytes and slight decrease of CFU-Mk, whereas ANP32A overexpression had an opposite but marginal effect (Supplementary Fig. 2A -F). These observations suggest a dispensable role of ANP32A on normal megakaryopoiesis. This may be due to the compensatory effect of ANP32B and ANP32E as proposed previously 6 . In sharp contrast, ANP32A knockdown (shANP32A#1) in 6133/MPL W515L cells induced spontaneous megakaryocytic differentiation in the absence of phorbol 12-myristate 13-acetate (PMA) with increased CD41 and CD42 expression (Fig. 1c) , which was confirmed in multiple AMKL cell lines ( Supplementary Fig. 3A -F). Although ANP32A overexpression failed to promote K562 cell proliferation, it did impair PMA-induced megakaryocytic differentiation ( Supplementary Fig. 4A-C) . Furthermore, ANP32A knockdown significantly reduced colony-forming ability of these cells in soft agar (Fig. 1d) . Notably, ANP32A downregulation significantly impaired the ability of 6133/ MPL W515L cells to induce AMKL in mice 7 and improved the survival rate (Fig. 1e ). These observations indicate that ANP32A may be critical for AMKL cell to maintain hyper-proliferative and undifferentiated status and contribute to the pathogenesis of AMKL.
Mechanistically, ectopic expression of ANP32A dampened the induction of RUNX1 and FLI1 and inhibited extracellular-signal-regulated kinase (ERK) activation by phorbol myristate acetate (PMA) (Fig. 2a) . In contrast, ANP32A downregulation caused an opposite phenotype (Fig. 2b) . These findings were consistent to previous reports showing that PMA induces activation of mitogenactivated protein kinase/ERK and stress-activated protein kinase/c-Jun NH(2)-terminal kinase pathways and subsequently regulate the expression of RUNX1 and FLI1 to promote megakaryopoiesis 8, 9 . Noticeably, further RUNX1 knockdown (shANP32A#3+shRUNX1) or FLI1 knockdown (shANP32A#3+shFLI1) efficiently abrogated shANP32A#3-induced megakaryocytic differentiation (Fig. 2c, Supplementary Fig. 5 ). Moreover, ERK inhibitor PD98059 significantly suppressed the induction of RUNX1 and FLI1 expression and abolished shANP32A#3-induced megakaryocytic differentiation (Fig. 2d, e) . Interestingly, ANP32A knockdown in primary AML cells increased the expression of RUNX1 and FLI1 and enhanced ERK phosphorylation while GATA1 was intact (Fig. 2f) . Our findings suggest that ANP32A may inhibit ERK and subsequently repress RUNX1 and FLI1 to promote megakaryocyte differentiation. dim , MEP (megakaryocyte-erythrocyte progenitor), CFU-Mk (colony-forming unit-megakaryocyte), and Mk (megakaryocytes) were analyzed and presented as log 2 expression. Expression data were obtained from online Bloodspot database (http://servers.binf.ku.dk/bloodspot/?gene=C5orf4&dataset=DMAP). b Quantitative RT-PCR analysis of ANP32A in MNCs from healthy donors (Normal, N=5) and two cases of AMKL patients (AMKL#1 and #2). The expression of ANP32A was normalized to GAPDH and presented as relative mRNA level. ***p < 0.001; NS: not significant. c Immunoblotting to detect ANP32A expression and flow cytometry to measure the expression of CD41 and CD42. Histograms were representative results of three independent experiments (duplicates) with similar results. d Scramble or Anp32a-knockdown (shAnp32a#1) 6133/MPL W515L cells were seeded in soft agar to measure the CFU. *p < 0.05. e Scramble or ANP32A-knockdown 6133/MPL W515L cells (shANP32A#1) were transplanted into semi-lethally irradiated mice through retro-orbital injection. The mice survival was observed up to 7 weeks In summary, our study reveals that ANP32A dysregulation may be a critical factor contributing to AMKL and ANP32A may be a good target for AMKL therapy. Previous studies showed that ANP32A bound to unmodified histone H3 and inhibited H3 acetylation 7 . Thus, ANP32A downregulation may potentially alter global epigenetic modifications. 
